

INFORME DE BÚSQUEDA DE PATENTES

N° de solicitud: nc2016/0005879

CRITERIOS PARA LA BÚSQUEDA (Anexar pantallazo o reporte en PDF, junto con los boléanos utilizados*. Para el caso de secuencias, anexar alineamientos)

PALABRAS CLAVE UTILIZADAS Antibody INF, interferon omega or alpha, neutralize

CLASIFICACIONES UTILIZADAS PARA LA BÚSQUEDA CIP: A61K 39/395, C12N 15/00

DOCUMENTOS CONSIDERADOS RELEVANTES (documentos patentes, literatura no patente, etc...)

Informes/Base de datos	N° de solicitud/ Autor**	Fecha de Publicación/ Presentación (DD/MM/AAAA)	Reiv. afectadas (Con indicación, si procede, de las partes relevantes o números de secuencias)	Categorías especiales de los documentos citados***
SIPI	NA			
ISA/IPEA (USPTO) EPO	US5317089	31/05/1994	NA	A
EPO	WO02/066649	29/08/2002	NA	A
	WO2009/135861	12/11/2009	NA	A
	EP0490233	17/06/1992	NA	A
ISA/IPEA (USPTO)	US2011/0206663	25/08/2011	NA	A
NCBI	US7662381	16/02/2010	NA	A
EPODOC	NA		NA	

*** Categorías especiales de documentos citados:

“A” documento que define el estado general de la técnica no considerado como particularmente relevante.
 “E” solicitud de patente o patente anterior pero publicada en la fecha de presentación internacional o en fecha posterior.
 “P” documento publicado antes de la fecha de presentación internacional pero con posterioridad a la fecha de prioridad reivindicada.

“X” documento particularmente relevante; la invención reivindicada no puede considerarse nueva o que implique una actividad inventiva por referencia al documento aisladamente considerado.
 “Y” documento particularmente relevante; la invención reivindicada no puede considerarse que implique una actividad inventiva cuando el documento se asocia a otro u otros documentos de la misma naturaleza, cuya combinación resulta evidente para un experto en la materia.

**** Indicar entre paréntesis la Autoridad que realizó la búsqueda o el informe preliminar Ejs: EPO, JP, INAPI.

Literatura no patente

**Se incluye entre otros, toda la referencia de la literatura no patente.

Fecha del reporte de búsqueda:

07/03/2018

Base de datos	NCBI nr
QUERY	SEQ 28

Description	Max score	Total score	Query cover	E value	Ident	Accession
immunoglobulin heavy chain [Homo sapiens]	225	225	100%	8e-74	94%	AAS86129.1
immunoglobulin variable region [Homo sapiens]	223	223	100%	3e-73	90%	ADX65431.1
immunoglobulin mu chain Vh5-D-J4 region [Homo sapiens]	219	219	100%	7e-72	91%	AAA58733.1
circulating B cell antibody heavy chain variable region [Homo sapiens]	219	219	100%	7e-72	90%	ABF83218.1
Chain H, CRYSTAL STRUCTURE OF ANTI-CCL17 ANTIBODY M116	221	221	100%	2e-71	93%	5WK2_H
circulating B cell antibody heavy chain variable region [Homo sapiens]	216	216	100%	8e-71	90%	ABF83397.1
immunoglobulin variable region [Homo sapiens]	216	216	98%	8e-71	92%	AAB36770.1
immunoglobulin heavy chain variable region [Homo sapiens]	216	216	100%	1e-70	92%	ACM63220.1
Ig heavy chain V region (clone DOB) - human (fragment)	216	216	100%	1e-70	90%	PH1558
immunoglobulin variable region [Homo sapiens]	215	215	100%	1e-70	91%	AAB36776.1
immunoglobulin heavy chain VHDJ region [Homo sapiens]	216	216	100%	2e-70	90%	BAC02108.1

Base de datos	NCBI Protein sequences derived from the Patent division of GenBank
QUERY	SEQ 28
entrez query	inf OR interferon

	Description	Max score	Total score	Query cover	E value	Ident	Accession
☐	Sequence 27 from patent US 7662381	204	204	100%	5e-71	86%	ADF08751.1
☐	Sequence 1 from patent US 9493570	202	202	100%	6e-70	85%	ATJ11891.1
☐	Sequence 42 from patent US 7662381	194	194	80%	5e-67	98%	ADF08758.1
☐	Sequence 29 from patent US 8258263	200	200	100%	2e-63	77%	AFS93467.1
☐	Sequence 31 from patent US 8258263	200	200	100%	2e-63	77%	AFS93468.1
☐	Sequence 2 from patent US 9758585	185	185	100%	2e-63	79%	AVA77771.1
☐	Sequence 33 from patent US 8258263	200	200	100%	2e-63	77%	AFS93469.1
☐	Sequence 35 from patent US 8258263	200	200	100%	3e-63	77%	AFS93470.1
☐	Sequence 1 from patent US 8258263	200	200	100%	3e-63	77%	AFS93451.1
☐	Sequence 4 from patent US 9758585	185	185	100%	3e-59	79%	AVA77773.1

Base de datos	NCBI nr
QUERY	SEQ 150

	Description	Max score	Total score	Query cover	E value	Ident	Accession
☐	immunoglobulin heavy chain variable region [Homo sapiens]	199	199	100%	1e-64	94%	AFK77956.1
☐	Chain L, Crystal Structure Of Human Germline Antibody Igkv1-69/igkv1-39	203	203	100%	1e-64	94%	5I15_L
☐	immunoglobulin light chain variable region [Homo sapiens]	199	199	100%	2e-64	94%	AAK94805.1
☐	Chain L, Crystal Structure Of Human Germline Antibody 5-51/o12	202	202	100%	2e-64	94%	4KMT_L
☐	immunoglobulin G heavy chain variable region [Homo sapiens]	199	199	100%	2e-64	94%	AIT39017.1
☐	immunoglobulin kappa light chain variable region [Homo sapiens]	199	199	100%	2e-64	94%	ABA70776.1
☐	Ig kappa light chain (VJC) [Homo sapiens]	199	199	100%	3e-64	93%	CAA51145.1
☐	immunoglobulin light chain variable region [Homo sapiens]	199	199	100%	3e-64	94%	CAA59085.1
☐	immunoglobulin kappa light chain [Homo sapiens]	199	199	100%	3e-64	94%	BAH04698.1
☐	immunoglobulin kappa light chain [Homo sapiens]	198	198	100%	3e-64	94%	BAH04695.1

Base de datos	NCBI Protein sequences derived from the Patent division of GenBank
QUERY	SEQ 150
entrez query	inf OR interferon

	Description	Max score	Total score	Query cover	E value	Ident	Accession
☐	Sequence 392 from patent US 9611322	191	191	99%	3e-66	93%	AUE31695.1
☐	Sequence 234 from patent US 9611322	193	193	99%	1e-65	93%	AUE31608.1
☐	Sequence 4 from patent US 7582445	192	192	100%	1e-66	91%	ACW43778.1
☐	Sequence 8 from patent US 8980267	196	196	100%	3e-66	91%	AKX26918.1
☐	Sequence 43 from patent US 7662381	161	161	87%	2e-54	87%	ADF08759.1
☐	Sequence 23 from patent US 7619070	189	189	100%	2e-65	86%	ADA40635.1
☐	Sequence 25 from patent US 7619070	189	189	100%	3e-65	86%	ADA40637.1
☐	Sequence 10 from patent US 9783589	183	183	100%	8e-63	86%	AVB91833.1
☐	Sequence 35 from patent US 7226903	181	181	100%	4e-62	86%	ABU26036.1
☐	Sequence 2 from patent US 8980267	183	183	100%	2e-61	86%	AKX26912.1
☐	Sequence 49 from patent US 8258263	183	183	100%	3e-61	86%	AFS93477.1
☐	Sequence 14 from patent US 9783589	156	156	87%	2e-52	85%	AVB91837.1

Base de datos	EPODOC
---------------	--------

[SS 2] antibody and inf

Results in EPODOC **21**

[SS 3] interferon and 2

Results in EPODOC **8**

[SS 4] 3 and neutralize

Results in EPODOC **0**

[SS 5] 3 and neutralize

Results in EPODOC **0**

[SS 6] 3 and pd<20140623

Results in EPODOC **8**

[SS 7] 3 and omega

Results in EPODOC **0**

LENS-FINDER	SEQ 28			
Patent Number	Title	Publication Date	SEQ ID NO	Local % Id
US 2007 0014720 A1	Antibodies directed to CD20 and uses thereof	18/01/07	26	91.8%
US 2007 0014720 A1	Antibodies directed to CD20 and uses thereof	18/01/07	30	91.8%
US 2010 0184959 A1	Polypeptide Variants	22/07/10	26	91.8%
US 2011 0129412 A1	Antibodies Directed to CD20 and Uses Thereof	02/06/11	26	91.8%
US 2011 0129412 A1	Antibodies Directed to CD20 and Uses Thereof	02/06/11	30	91.8%
JP 2008541758 A		27/11/08	83	91.8%
JP 2008541758 A		27/11/08	85	91.8%
WO 2006 130458 A2	ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	07/12/06	26	91.8%
WO 2006 130458 A2	ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	07/12/06	30	91.8%
WO 2008 114011 A2	POLYPEPTIDE VARIANTS	25/09/08	26	91.8%
CA 2610234 A1	ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	07/12/06	26	91.8%
CA 2610234 A1	ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	07/12/06	30	91.8%
US 2007 0014720 A1	Antibodies directed to CD20 and uses thereof	18/01/07	2	91.%
US 2011 0129412 A1	Antibodies Directed to CD20 and Uses Thereof	02/06/11	2	91.%
JP 2008541758 A		27/11/08	71	91.%
WO 2006 130458 A2	ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	07/12/06	2	91.%
CA 2610234 A1	ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	07/12/06	2	91.%
US 2007 0014720 A1	Antibodies directed to CD20 and uses thereof	18/01/07	14	91.%
US 2011 0129412 A1	Antibodies Directed to CD20 and Uses Thereof	02/06/11	14	91.%
JP 2008541758 A		27/11/08	77	91.%
WO 2006 130458 A2	ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	07/12/06	14	91.%
CA 2610234 A1	ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	07/12/06	14	91.%
US 2005 0058649 A1	Antibodies directed to phospholipase A2 and uses thereof	17/03/05	145	92.6%
JP 2006517188 A		20/07/06	145	92.6%
CA 2508214 A1	ANTIBODIES DIRECTED TO PHOSPHOLIPASE A2 AND USES THEREOF	17/06/04	145	92.6%
US 2005 0058649 A1	Antibodies directed to phospholipase A2 and uses thereof	17/03/05	7	91.7%
JP 2006517188 A		20/07/06	26	91.7%
CA 2508214 A1	ANTIBODIES DIRECTED TO PHOSPHOLIPASE A2 AND USES THEREOF	17/06/04	7	91.7%
US 2011 0318339 A1	ANTI-DLL4 ANTIBODIES AND USES THEREOF	29/12/11	390	92.6%
US 2012 0316071 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	13/12/12	387	92.6%
JP 2012508017 A		05/04/12	649	92.6%
JP 2013510164 A		21/03/13	1500	92.6%
WO 2010 054010 A1	ANTI-DLL4 ANTIBODIES AND USES THEREOF	14/05/10	390	92.6%
WO 2011 056997 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	387	92.6%
CA 2742969 A1	ANTI-DLL4 ANTIBODIES AND USES THEREOF	14/05/10	390	92.6%
CA 2780221 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	387	92.6%
US 2008 0124345 A1	Antibodies directed to HER-3 and uses thereof	29/05/08	18	90.9%
US 2010 0183631 A1	Antibodies Directed to HER-3 and Uses Thereof	22/07/10	18	90.9%
US 2011 0229406 A1	Material and methods for treating or preventing HER-3 associated diseases	22/09/11	18	90.9%
US 2012 0058122 A1	Antibodies Directed to HER-3 and Uses Thereof	08/03/12	18	90.9%
US 2012 0156130 A1	USE OF HER3 BINDING AGENTS IN PROSTATE TREATMENT	21/06/12	18	90.9%
US 2014 0017166 A1	MATERIAL AND METHODS FOR TREATING OR PREVENTING HER-3 ASSOCIATED DISEASES	16/01/14	18	90.9%
US 7705130 B2	Antibodies directed to HER-3 and uses thereof	27/04/10	18	90.9%
JP 2009521913 A		11/06/09	127	90.9%
WO 2007 077028 A2	ANTIBODIES DIRECTED TO HER-3 AND USES THEREOF	12/07/07	18	90.9%
JP 2013056884 A	ANTIBODY DIRECTED TO HER-3 AND USE THEREOF	28/03/13	127	90.9%
JP 2013510868 A		28/03/13	128	90.9%
JP 2014012006 A	ANTIBODY INDUCED AGAINST HER-3 AND USE THEREOF	23/01/14	127	90.9%
JP 2013540694 A		07/11/13	128	90.9%
WO 2011 060206 A2	MATERIAL AND METHODS FOR TREATING OR PREVENTING HER-3 ASSOCIATED DISEASES	19/05/11	18	90.9%
WO 2012 018404 A2	USE OF HER3 BINDING AGENTS IN PROSTATE TREATMENT	09/02/12	18	90.9%
WO 2013 124419 A1	HER3 INHIBITOR FOR MODULATING RADIOSENSITIVITY	29/08/13	18	90.9%
CA 2780935 A1	MATERIAL AND METHODS FOR TREATING OR PREVENTING HER-3 ASSOCIATED DISEASES	19/05/11	18	90.9%
CA 2865256 A1	HER3 INHIBITOR FOR MODULATING RADIOSENSITIVITY	29/08/13	18	90.9%
US 2006 0293506 A1	Antibodies directed to PDGFD and uses thereof	28/12/06	313	88.1%
US 7135174 B2	Antibodies directed to PDGFD and uses thereof	14/11/06	313	88.1%
JP 2005530684 A		13/10/05	313	88.1%
CA 2472826 A1	ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF	17/07/03	313	88.1%
US 2012 0058906 A1	COMBINATORIAL ANTIBODY LIBRARIES AND USES THEREOF	08/03/12	1804	90.9%
US 2012 0316071 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	13/12/12	2142	90.9%
JP 2012508016 A		05/04/12	2811	90.9%
JP 2013510164 A		21/03/13	2149	90.9%
WO 2010 054007 A1	COMBINATORIAL ANTIBODY LIBRARIES AND USES THEREOF	14/05/10	1804	90.9%
WO 2011 056997 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	2142	90.9%
CA 2742968 A1	COMBINATORIAL ANTIBODY LIBRARIES AND USES THEREOF	14/05/10	1804	90.9%
CA 2780221 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	2142	90.9%
US 2006 0246071 A1	Antibodies directed to angiopoietin-2 and uses thereof	02/11/06	27	88.4%
US 2008 0267971 A1	Antibodies Directed to Angiopoietin-2 and Uses Thereof	30/10/08	27	88.4%
US 2012 0052073 A1	Antibodies Directed to Angiopoietin-2 And Uses Thereof	01/03/12	27	88.4%

US 2013 0171160 A1	ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF	04/07/13	27	88.4%
US 7973140 B2	Antibodies directed to angiotensin-2 and uses thereof	05/07/11	27	88.4%
JP 2008523841 A		10/07/08	292	88.4%
WO 2006 068953 A2	ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF	29/06/06	27	88.4%
JP 2012050455 A	ANTIBODY DIRECTED TO ANGIOPOIETIN-2 AND USE THEREOF	15/03/12	292	88.4%
EP 2284194 A1	Antibodies directed to angiotensin-2 and uses thereof	16/02/11	27	88.4%
CA 2595610 C	ANTIBODIES DIRECTED TO ANGIOPOIETIN-2 AND USES THEREOF	05/03/13	27	88.4%
US 2011 0318339 A1	ANTI-DLL4 ANTIBODIES AND USES THEREOF	29/12/11	391	91.8%
US 2012 0316071 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	13/12/12	388	91.8%
JP 2012508017 A		05/04/12	650	91.8%
JP 2013510164 A		21/03/13	1501	91.8%
WO 2010 054010 A1	ANTI-DLL4 ANTIBODIES AND USES THEREOF	14/05/10	391	91.8%
WO 2011 056997 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	388	91.8%
CA 2742969 A1	ANTI-DLL4 ANTIBODIES AND USES THEREOF	14/05/10	391	91.8%
CA 2780221 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	388	91.8%
US 2013 0216548 A1	MONOCLONAL ANTIBODIES AGAINST C-MET	22/08/13	105	91.7%
US 2013 0216548 A1	MONOCLONAL ANTIBODIES AGAINST C-MET	22/08/13	175	91.7%
JP 2013529059 A		18/07/13	105	91.7%
JP 2013529059 A		18/07/13	175	91.7%
JP 2013529059 A		18/07/13	268	91.7%
WO 2011 110642 A2	MONOCLONAL ANTIBODIES AGAINST C-MET	15/09/11	105	91.7%
WO 2011 110642 A2	MONOCLONAL ANTIBODIES AGAINST C-MET	15/09/11	175	91.7%
CA 2791863 A1	MONOCLONAL ANTIBODIES AGAINST C-MET	15/09/11	105	91.7%
CA 2791863 A1	MONOCLONAL ANTIBODIES AGAINST C-MET	15/09/11	175	91.7%
US 2004 0105862 A1	Human TIMP-1 antibodies	03/06/04	166	90.1%
US 2007 0160614 A1	Human TIMP-1 antibodies	12/07/07	166	90.1%
US 2009 0017037 A1	Human TIMP-1 Antibodies	15/01/09	166	90.1%
US 2011 0262429 A1	HUMAN TIMP-1 ANTIBODIES	27/10/11	166	90.1%
US 2013 0302340 A1	HUMAN TIMP-1 ANTIBODIES	14/11/13	166	90.1%
US 2014 0086935 A1	Human TIMP-1 Antibodies	27/03/14	166	90.1%
US 7091323 B2	Human TIMP-1 antibodies	15/08/06	166	90.1%
US 7432364 B2	Human TIMP-1 antibodies	07/10/08	166	90.1%
US 7993849 B2	Human TIMP-1 antibodies	09/08/11	166	90.1%
JP 2004529647 A		30/09/04	340	90.1%
JP 2009195233 A	HUMAN TIMP-1 ANTIBODY	03/09/09	340	90.1%
CA 2445168 A1	HUMAN TIMP-1 ANTIBODIES	31/10/02	166	90.1%
US 2007 0014720 A1	Antibodies directed to CD20 and uses thereof	18/01/07	34	90.1%
US 2011 0129412 A1	Antibodies Directed to CD20 and Uses Thereof	02/06/11	34	90.1%
JP 2008541758 A		27/11/08	87	90.1%
WO 2006 130458 A2	ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	07/12/06	34	90.1%
CA 2610234 A1	ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	07/12/06	34	90.1%
US 2007 0014720 A1	Antibodies directed to CD20 and uses thereof	18/01/07	42	91.9%
US 2011 0129412 A1	Antibodies Directed to CD20 and Uses Thereof	02/06/11	42	91.9%
JP 2008541758 A		27/11/08	91	91.9%
WO 2006 130458 A2	ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	07/12/06	42	91.9%
CA 2610234 A1	ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	07/12/06	42	91.9%
US 2011 0293619 A1	CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY	01/12/11	532	91.7%
JP 2012504403 A		23/02/12	734	91.7%
WO 2010 037836 A2	CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY	08/04/10	532	91.7%
CA 2738565 A1	CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY	08/04/10	532	91.7%
US 2004 0033229 A1	PSMA antibodies and protein multimers	19/02/04	27	91.7%
US 2004 0161776 A1	PSMA formulations and uses thereof	19/08/04	27	91.7%
US 2005 0215472 A1	PSMA formulations and uses thereof	29/09/05	27	91.7%
US 2007 0160617 A1	PSMA antibody-drug conjugates	12/07/07	27	91.7%
US 2008 0286284 A1	Compositions of PSMA antibodies	20/11/08	27	91.7%
US 2011 0165081 A1	PSMA ANTIBODIES AND USES THEREOF	07/07/11	27	91.7%
US 2011 0250216 A1	METHODS FOR KILLING PSMA-EXPRESSING, TAXANE-RESISTANT CANCER CELLS	13/10/11	27	91.7%
US 7850971 B2	PSMA antibodies and protein multimers	14/12/10	27	91.7%
US 8114965 B2	Compositions of PSMA antibodies	14/02/12	27	91.7%
US 8470330 B2	PSMA antibodies and uses thereof	25/06/13	27	91.7%
JP 2005523683 A		11/08/05	30	91.7%
WO 2005 042029 A2	PSMA FORMULATIONS AND USES THEREOF	12/05/05	27	91.7%
JP 2008546792 A		25/12/08	30	91.7%
WO 2007 002222 A2	PSMA ANTIBODY-DRUG CONJUGATES	04/01/07	27	91.7%
JP 2009102443 A	PSMA ANTIBODIES AND PROTEIN MULTIMERS	14/05/09	30	91.7%
JP 2012245010 A	PSMA ANTIBODY AND PROTEIN MULTIMER	13/12/12	30	91.7%
JP 2013100314 A	PSMA ANTIBODY-DRUG CONJUGATE	23/05/13	30	91.7%
WO 2010 027513 A2	METHODS FOR KILLING PSMA-EXPRESSING, TAXANE-RESISTANT CANCER CELLS	11/03/10	27	91.7%
CA 2543703 A1	PSMA FORMULATIONS AND USES THEREOF	12/05/05	27	91.7%
CA 2612762 C	PSMA ANTIBODY-DRUG CONJUGATES	10/12/13	27	91.7%
US 2011 0318339 A1	ANTI-DLL4 ANTIBODIES AND USES THEREOF	29/12/11	897	90.9%
US 2012 0316071 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	13/12/12	2902	90.9%
JP 2012508017 A		05/04/12	900	90.9%
JP 2013510164 A		21/03/13	2909	90.9%

WO 2010 054010 A1	ANTI-DLL4 ANTIBODIES AND USES THEREOF	14/05/10	897	90.9%
WO 2011 056997 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	2902	90.9%
CA 2742969 A1	ANTI-DLL4 ANTIBODIES AND USES THEREOF	14/05/10	897	90.9%
CA 2780221 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	2902	90.9%
US 2006 0293506 A1	Antibodies directed to PDGFD and uses thereof	28/12/06	27	87.3%
US 2006 0293506 A1	Antibodies directed to PDGFD and uses thereof	28/12/06	214	87.3%
US 2006 0293506 A1	Antibodies directed to PDGFD and uses thereof	28/12/06	249	87.3%
US 7135174 B2	Antibodies directed to PDGFD and uses thereof	14/11/06	27	87.3%
US 7135174 B2	Antibodies directed to PDGFD and uses thereof	14/11/06	214	87.3%
US 7135174 B2	Antibodies directed to PDGFD and uses thereof	14/11/06	249	87.3%
JP 2005530684 A		13/10/05	176	87.3%
JP 2005530684 A		13/10/05	214	87.3%
JP 2005530684 A		13/10/05	249	87.3%
JP 2006511471 A		06/04/06	73	87.3%
CA 2472826 A1	ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF	17/07/03	27	87.3%
CA 2472826 A1	ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF	17/07/03	214	87.3%
CA 2472826 A1	ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF	17/07/03	249	87.3%
CA 2499207 A1	METHOD FOR THE TREATMENT OF NEPHRITIS USING ANTI-PDGF-DD ANTIBODIES	25/03/04	34	87.3%
US 2011 0318339 A1	ANTI-DLL4 ANTIBODIES AND USES THEREOF	29/12/11	383	91.8%
US 2012 0058906 A1	COMBINATORIAL ANTIBODY LIBRARIES AND USES THEREOF	08/03/12	3724	91.8%
US 2012 0316071 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	13/12/12	380	91.8%
JP 2012508016 A		05/04/12	3739	91.8%
JP 2012508017 A		05/04/12	642	91.8%
JP 2013510164 A		21/03/13	1493	91.8%
WO 2010 054007 A1	COMBINATORIAL ANTIBODY LIBRARIES AND USES THEREOF	14/05/10	3724	91.8%
WO 2010 054010 A1	ANTI-DLL4 ANTIBODIES AND USES THEREOF	14/05/10	383	91.8%
WO 2011 056997 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	380	91.8%
CA 2742968 A1	COMBINATORIAL ANTIBODY LIBRARIES AND USES THEREOF	14/05/10	3724	91.8%
CA 2742969 A1	ANTI-DLL4 ANTIBODIES AND USES THEREOF	14/05/10	383	91.8%
CA 2780221 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	380	91.8%
US 2011 0318339 A1	ANTI-DLL4 ANTIBODIES AND USES THEREOF	29/12/11	400	91.8%
US 2012 0316071 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	13/12/12	397	91.8%
JP 2012508017 A		05/04/12	659	91.8%
JP 2013510164 A		21/03/13	1510	91.8%
WO 2010 054010 A1	ANTI-DLL4 ANTIBODIES AND USES THEREOF	14/05/10	400	91.8%
WO 2011 056997 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	397	91.8%
CA 2742969 A1	ANTI-DLL4 ANTIBODIES AND USES THEREOF	14/05/10	400	91.8%
CA 2780221 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	397	91.8%
US 2011 0318339 A1	ANTI-DLL4 ANTIBODIES AND USES THEREOF	29/12/11	401	91.8%
US 2012 0316071 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	13/12/12	398	91.8%
JP 2012508017 A		05/04/12	660	91.8%
JP 2013510164 A		21/03/13	1511	91.8%
WO 2010 054010 A1	ANTI-DLL4 ANTIBODIES AND USES THEREOF	14/05/10	401	91.8%
WO 2011 056997 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	398	91.8%
CA 2742969 A1	ANTI-DLL4 ANTIBODIES AND USES THEREOF	14/05/10	401	91.8%
CA 2780221 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	398	91.8%
US 2012 0108795 A1	Antibodies Binding Human Collagen II	03/05/12	68	93.4%
US 8394378 B2	Antibodies binding human collagen II	12/03/13	68	93.4%
JP 2013542722 A		28/11/13	68	93.4%
EP 2621950 A2	ANTIBODIES BINDING HUMAN COLLAGEN II	07/08/13	68	93.4%
WO 2012 047583 A2	ANTIBODIES BINDING HUMAN COLLAGEN II	12/04/12	68	93.4%
US 2011 0318339 A1	ANTI-DLL4 ANTIBODIES AND USES THEREOF	29/12/11	132	91.8%
US 2012 0316071 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	13/12/12	89	91.8%
JP 2012508017 A		05/04/12	391	91.8%
JP 2013510164 A		21/03/13	1202	91.8%
WO 2010 054010 A1	ANTI-DLL4 ANTIBODIES AND USES THEREOF	14/05/10	132	91.8%
WO 2011 056997 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	89	91.8%
CA 2742969 A1	ANTI-DLL4 ANTIBODIES AND USES THEREOF	14/05/10	132	91.8%
CA 2780221 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	89	91.8%
US 2012 0058906 A1	COMBINATORIAL ANTIBODY LIBRARIES AND USES THEREOF	08/03/12	1797	91.7%
US 2012 0316071 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	13/12/12	2136	91.7%
JP 2012508016 A		05/04/12	2804	91.7%
JP 2013510164 A		21/03/13	2143	91.7%
WO 2010 054007 A1	COMBINATORIAL ANTIBODY LIBRARIES AND USES THEREOF	14/05/10	1797	91.7%
WO 2011 056997 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	2136	91.7%
CA 2742968 A1	COMBINATORIAL ANTIBODY LIBRARIES AND USES THEREOF	14/05/10	1797	91.7%
CA 2780221 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	2136	91.7%
US 2011 0318339 A1	ANTI-DLL4 ANTIBODIES AND USES THEREOF	29/12/11	387	91.8%
US 2012 0316071 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	13/12/12	384	91.8%
JP 2012508017 A		05/04/12	646	91.8%
JP 2013510164 A		21/03/13	1497	91.8%
WO 2010 054010 A1	ANTI-DLL4 ANTIBODIES AND USES THEREOF	14/05/10	387	91.8%
WO 2011 056997 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	384	91.8%
CA 2742969 A1	ANTI-DLL4 ANTIBODIES AND USES THEREOF	14/05/10	387	91.8%
CA 2780221 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	384	91.8%

US 2011 0318339 A1	ANTI-DLL4 ANTIBODIES AND USES THEREOF	29/12/11	399	91.8%
US 2012 0316071 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	13/12/12	396	91.8%
JP 2012508017 A		05/04/12	658	91.8%
JP 2013510164 A		21/03/13	1509	91.8%
WO 2010 054010 A1	ANTI-DLL4 ANTIBODIES AND USES THEREOF	14/05/10	399	91.8%
WO 2011 056997 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	396	91.8%
CA 2742969 A1	ANTI-DLL4 ANTIBODIES AND USES THEREOF	14/05/10	399	91.8%
CA 2780221 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	396	91.8%
US 2011 0318339 A1	ANTI-DLL4 ANTIBODIES AND USES THEREOF	29/12/11	397	91.8%
US 2012 0316071 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	13/12/12	394	91.8%
JP 2012508017 A		05/04/12	656	91.8%
JP 2013510164 A		21/03/13	1507	91.8%
WO 2010 054010 A1	ANTI-DLL4 ANTIBODIES AND USES THEREOF	14/05/10	397	91.8%
WO 2011 056997 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	394	91.8%
CA 2742969 A1	ANTI-DLL4 ANTIBODIES AND USES THEREOF	14/05/10	397	91.8%
CA 2780221 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	394	91.8%
US 2009 0304590 A1	Therapeutic compositions and methods	10/12/09	323	89.3%
WO 2009 055074 A2	THERAPEUTIC COMPOSITIONS AND METHODS	30/04/09	323	89.3%
US 2012 0058906 A1	COMBINATORIAL ANTIBODY LIBRARIES AND USES THEREOF	08/03/12	1803	91.8%
JP 2012508016 A		05/04/12	2810	91.8%
WO 2010 054007 A1	COMBINATORIAL ANTIBODY LIBRARIES AND USES THEREOF	14/05/10	1803	91.8%
CA 2742968 A1	COMBINATORIAL ANTIBODY LIBRARIES AND USES THEREOF	14/05/10	1803	91.8%
US 2007 0014720 A1	Antibodies directed to CD20 and uses thereof	18/01/07	144	90.9%
US 2011 0129412 A1	Antibodies Directed to CD20 and Uses Thereof	02/06/11	144	90.9%
JP 2008541758 A		27/11/08	144	90.9%
WO 2006 130458 A2	ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	07/12/06	144	90.9%
CA 2610234 A1	ANTIBODIES DIRECTED TO CD20 AND USES THEREOF	07/12/06	144	90.9%
US 2011 0318339 A1	ANTI-DLL4 ANTIBODIES AND USES THEREOF	29/12/11	385	91.8%
US 2012 0316071 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	13/12/12	382	91.8%
JP 2012508017 A		05/04/12	644	91.8%
JP 2013510164 A		21/03/13	1495	91.8%
WO 2010 054010 A1	ANTI-DLL4 ANTIBODIES AND USES THEREOF	14/05/10	385	91.8%
WO 2011 056997 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	382	91.8%
CA 2742969 A1	ANTI-DLL4 ANTIBODIES AND USES THEREOF	14/05/10	385	91.8%
CA 2780221 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	382	91.8%
US 2012 0058906 A1	COMBINATORIAL ANTIBODY LIBRARIES AND USES THEREOF	08/03/12	1799	88.8%
US 2012 0316071 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	13/12/12	2138	88.8%
JP 2012508016 A		05/04/12	2806	88.8%
JP 2013510164 A		21/03/13	2145	88.8%
WO 2010 054007 A1	COMBINATORIAL ANTIBODY LIBRARIES AND USES THEREOF	14/05/10	1799	88.8%
WO 2011 056997 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	2138	88.8%
CA 2742968 A1	COMBINATORIAL ANTIBODY LIBRARIES AND USES THEREOF	14/05/10	1799	88.8%
CA 2780221 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	2138	88.8%
US 2011 0318339 A1	ANTI-DLL4 ANTIBODIES AND USES THEREOF	29/12/11	424	90.9%
US 2012 0316071 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	13/12/12	421	90.9%
JP 2012508017 A		05/04/12	683	90.9%
JP 2013510164 A		21/03/13	1534	90.9%
WO 2010 054010 A1	ANTI-DLL4 ANTIBODIES AND USES THEREOF	14/05/10	424	90.9%
WO 2011 056997 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	421	90.9%
CA 2742969 A1	ANTI-DLL4 ANTIBODIES AND USES THEREOF	14/05/10	424	90.9%
CA 2780221 A1	METHODS FOR AFFINITY MATURATION-BASED ANTIBODY OPTIMIZATION	12/05/11	421	90.9%
US 2013 0216548 A1	MONOCLONAL ANTIBODIES AGAINST C-MET	22/08/13	173	90.9%
JP 2013529059 A		18/07/13	173	90.9%
WO 2011 110642 A2	MONOCLONAL ANTIBODIES AGAINST C-MET	15/09/11	173	90.9%
CA 2791863 A1	MONOCLONAL ANTIBODIES AGAINST C-MET	15/09/11	173	90.9%
US 2013 0216548 A1	MONOCLONAL ANTIBODIES AGAINST C-MET	22/08/13	171	90.9%